Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Stockhouse Jun 11 05:00

Sector Spotlight: Orphan Drug Developers With Significant Upside

Stockhouse Jun 3 06:00

Analysts' Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics

Stockhouse May 28 06:00

Cardiol Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

Cardiol Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 23 10:48

Cardiol Therapeutics Inc: Canaccord Genuity raises price target from $6 to $8

Cardiol Therapeutics Inc: Canaccord Genuity raises price target from $6 to $8

Zhitong FinanceMay 22 23:36

Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure

Cardiol Therapeutics (CRDLTO) working on treatments for heart disease, on Tuesday said its Phase II trial evaluating the impact of CardiolRx on myocardial recovery in patients with acute myocarditis (

MT NewswiresMay 14 10:30